<DOC>
	<DOCNO>NCT00767585</DOCNO>
	<brief_summary>The aim study determine effect aromatase inhibitor therapy bone mineral density compare effect tamoxifen hormonal therapy .</brief_summary>
	<brief_title>An Open Label Non-Interventional Evaluation Effect Adjuvant Hormonal Treatment Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors Bone Mineral Density Bone Fracture Rate Daily Practice</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Women age 5565 year , diagnose invasive early breast cancer : Surgery , chemo and/or radiotherapy conclude less 6 month ago Women hormoneindependent breast cancer : Surgery , chemo and/or radiotherapy conclude 2436 month 5466 month Women hormonedependent breast cancer : Adjuvant therapy tamoxifen initiate 2436 5466 month Adjuvant therapy aromatase inhibitor initiate 2436 5466 month Switch tamoxifen aromatase inhibitor initiated 2436 month Women receive active treatment osteoporosis Women evidence breast cancer recurrence</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>aromatase inhibitor</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>osteoporosis</keyword>
</DOC>